2002
Estrogen Replacement Therapy and Risk of Ovarian Cancer in Postmenopausal Women—Reply
Search citation statements
Paper Sections
Select...
10
1
1
0
Citation Types
0
3
0
0
Year Published
2003
2015
Publication Types
Select...
11
1
Relationship
0
12
Authors
Journals
Cited by 9 publications
(3 citation statements)
References 4 publications
0
3
0
0
“…However, there have been no clinical trials directly comparing tamoxifen and raloxifene. The results of the STAR (Study of Tamoxifen and Raloxifene) trials (47), in which postmenopausal women at increased risk for breast cancer are being randomly assigned to receive either tamoxifen or raloxifene for a 5-year period, are awaited with great interest.…”
Section: Discussionmentioning
confidence: 99%
“…However, there have been no clinical trials directly comparing tamoxifen and raloxifene. The results of the STAR (Study of Tamoxifen and Raloxifene) trials (47), in which postmenopausal women at increased risk for breast cancer are being randomly assigned to receive either tamoxifen or raloxifene for a 5-year period, are awaited with great interest.…”
Section: Discussionmentioning
confidence: 99%
“…The use of hormone replacement therapy (HRT) recently was linked to an increased risk of ovarian cancer. Women who used estrogen-only therapy, especially those who used estrogen replacement for more than 10 years, were at significantly increased risk for developing ovarian cancer (Lacey et al, 2002). Additional studies evaluating the relationship between HRT and ovarian cancer risk have not been consistent.…”
Section: Hormone Replacement Therapymentioning
confidence: 99%
“…Evidence has accumulated from studies involving cell cultures, animal models, and epidemiology showing a strong linkage between exposure to estrogens and breast cancer risk [2,3]. Estrogens have also been found to be involved in colon cancer [4] and ovarian cancer, especially when connected to postmenopausal estrogen treatment [5,6].…”
Section: Introductionmentioning
confidence: 99%
